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Abstract | Macrophages are a heterogeneous group of cells that are capable of carrying out distinct functions in different tis-
sues, as well as in different locations within a given tissue. Some of these tissue macrophages lie on, or close to, the outer 
(abluminal) surface of blood vessels and perform several crucial functions at this interface between the tissue and the blood. In 
steady-state tissues, these perivascular macrophages maintain tight junctions between endothelial cells and limit vessel permea-
bility, phagocytose potential pathogens before they enter tissues from the blood and limit inappropriate inflammation. They 
also have a multifaceted role in important diseases such as cancer, Alzheimer disease, multiple sclerosis and type 1 diabetes. 
Here, we examine the important functions of perivascular macrophages in various adult tissues and describe how these func-
tions are perturbed in a broad array of pathological conditions. 
[H1] Introduction 
Macrophages are present in all organs of the body, where they carry out distinct functions depending on their location and phenotype1. 
During normal vascular development, macrophages directly interact with, and modulate, the developing vasculature2,3. In many adult 
tissues, some macrophages are seen to establish close contacts with blood vessels and to have an array of functions that are important 
for both tissue homeostasis and pathology. Whereas in some organs such as the brain these perivascular macrophages (PVMs) can 
be distinguished from other tissue macrophages on the basis of both their proximity to blood vessels and their expression of certain 
markers4, in other tissues such as the skin5 PVMs have been defined largely on the basis of their location. As there is currently no 
general definition for PVMs, for the purposes of this Review, we define them as macrophages that either make direct contact with the 
abluminal surface of blood vessels (TABLES 1,2) or are located within approximately one cell thickness from it (within 15 µm of a blood 
vessel, as defined previously for PVMs in the dermis5). 
The exact nature of the physical interaction between PVMs and blood vessels can vary in different tissue sites. For example, PVMs 
can wrap around a blood vessel with or without making direct contact with it, can be either inside or outside the basement membrane 
of the blood vessel and can extend their filopodia along or through the vessel wall into the blood vessel lumen (FIG. 1). The relevance of 
these anatomical variations to the functions of PVMs in different tissues is discussed below. 
In adult steady-state tissues, PVMs often have important functions related to their perivascular position, such as the regulation of 
vascular permeability, the scavenging of blood-borne pathogens and the control of the movement of other leukocytes across the vas-
culature. Although PVMs may express some distinctive phenotypic markers in certain tissues (TABLE 1), they do not share a single, 
common phenotype. This is likely to result from the exposure of PVMs to a diverse array of signals in distinct tissues, as well as possible 
differences in their ontogeny (BOX 1). 
Importantly, PVMs have recently been shown to have several essential roles in the maintenance of steady-state tissues and to 
contribute to the aetiology and/or progression of several pathological conditions6–8. In this Review, we first examine the functions, 
phenotype, regulation and origin of PVMs in various steady-state tissues and then contrast these properties with those of PVMs that 
contribute to the pathobiology of various diseased states. 
[H1] Functions in steady-state adult tissues 
Outlined below are the functions that are known to be carried out by PVMs in various healthy adult tissues. Some of these functions 
may also be carried out by most tissue-resident macrophages, whereas other functions are specific to PVMs and are associated with 
their proximity to the blood vessel endothelium. 
[H2] Regulation of blood vessel permeability. Pericytes, which wrap around the endothelial cells of small blood vessels, have long been 
known to regulate vascular permeability9. However, PVMs may also contribute to this important aspect of vascular homeostasis. For 
example, when PVMs in the stria vascularis of the cochlea are depleted, tight junctions between blood vessel endothelial cells become 
unstable, resulting in increased vessel permeability and, ultimately, the loss of hearing10. Furthermore, macrophages isolated from the 
cochlea can limit the permeability of monolayers of cochlear endothelial cells in vitro through the release of pigment epithelium-derived 
factor (PEDF), which induces endothelial cell expression of proteins involved in tight junctions, such as occludin and vascular endo-
thelial cadherin (VE-cadherin; also known as CDH5)10. Furthermore, injection of a small interfering RNA that targets Serpinf1 (which 
encodes PEDF) through the tympanic membrane of mice efficiently targeted PVMs in the stria vascularis and resulted in a reduction 
in tight junctions between endothelial cells10, which suggests that the release of PEDF by PVMs limits vascular permeability in this 
tissue. Similarly, PVMs are a prominent component of the blood–brain barrier (BBB)11 (FIG. 1a), and the permeability of monolayers of 
endothelial cells isolated from mouse brain is markedly reduced following their co-culture with macrophages12. However, it remains to 
be seen whether macrophage-derived PEDF also limits vessel permeability in the BBB. 
PVMs have also been implicated in the regulation of blood vessel permeability in the mesentery, a double fold of the peritoneum13. 
Csf1op/op mice have a naturally occurring gene mutation that results in the lack of macrophage colony-stimulating factor 1 (CSF1), a 
cytokine that sustains the differentiation and viability of macrophages14. These CSF1-deficient mice have a reduced number of macro-
phages in their tissues, including PVMs around mesenteric vessels13. The lack of mesenteric PVMs in Csf1op/op mice was associated 
with vascular instability and increased permeability, a phenotype that could be reversed through the adoptive transfer of macrophages13 
that express high levels of the scavenging receptor macrophage mannose receptor 1 (MRC1; also known as CLEC13D)15. Mesenteric 
PVMs also express high levels of arginase 1 (Arg1) mRNA, which, together with MRC1 expression, led the authors to describe these 
PVMs as having undergone alternative (M2) macrophage activation rather than classical (M1) macrophage activation. Infusion of Csf1op/op mice 
with macrophages lacking expression of MRC1 and Arg1 (M1-like macrophages) did not attenuate the increased vascular permeability 
in Csf1op/op mice13. MRC1hi Arg1-expressing macrophages could maintain endothelial cell junctions in vitro by limiting the phosphoryla-
tion of the endothelial cell adhesion molecule VE-cadherin13, which restricts vascular permeability both in vitro and in vivo16. The M1–
M2 classification of macrophage activation has been used widely since its inception in 2000 and assumes that M1 and M2 macrophages 
sit at opposing ends of a continuum of activation states17. However, it should be noted that this may under-represent the remarkable 
plasticity and diversity of tissue macrophages. Nevertheless, we have included use of this terminology when it was used by authors to 
describe their findings. 
[H2] Phagocytosis. PVMs are ideally positioned to detect and phagocytose potentially harmful, foreign agents as they cross the vas-
culature into tissues. In several mouse tissues such as the brain, retina, kidneys, cochlea, testis, pineal gland and pancreatic islets of 
Langerhans, macrophages have been shown to phagocytose fluorescently labelled macromolecules injected into the systemic circulation 
(a method that was used previously to define cells of the reticuloendothelial system). Macrophage uptake of such macromolecules in the 
perivascular niche has been visualized by both analysis of post-mortem tissue and, more recently, intravital imaging in live mice over 
time18–25. For example, in the kidney, PVMs are situated between the abluminal surface of endothelial cells and the basement mem-
brane of capillaries that surround the renal tubules and Bowman capsule (FIG. 1b). These PVMs have highly motile filopodia that extend 
along the capillary surface and scavenge molecules such as small immune complexes that are actively transported into the renal 
interstitium through the endothelium20. PVMs were observed to move along the abluminal surface of the blood vessel endothelium in 
the retina, scavenging potential pathogenic substances present in the perivascular space19 (FIG. 1c). Although perivascular myeloid cells 
in the islets of Langerhans in the pancreas were initially thought to be dendritic cells (DCs), they have now been shown to be macro-
phages24 that project their cytoplasmic extensions into the vessel lumen to take up substances from the blood25 (FIG. 1d). They may also 
be capable of phagocytosing dense core granules released by adjacent islet β-cells26. In the marginal zone of the spleen, highly phagocytic 
PVMs known as metallophilic macrophages phagocytose blood-borne pathogens such as viruses and bacteria, therefore limiting early 
haematogenic spread of the pathogen27–30. The proximity of these macrophages to T cell-rich and B cell-rich areas in the spleen may 
also enable PVMs to modulate adaptive immunity against invading pathogens, for example, by transferring antigens to cross-presenting 
CD8+ DCs31. However, the specific elimination of metallophilic macrophages did not compromise antigen presentation and T cell re-
sponses in one study28. Finally, macrophages in the myocardium of the heart make contact with both endothelial cells and cardiomyo-
cytes. The pattern of gene expression of these PVMs in mice indicates that they might have a role in the clearance of dead and dying 
cells32. It has been postulated that this phagocytic activity could be part of a broader role for these cells in the maintenance of the 
myocardium, as they also express genes that promote tissue repair and prevent fibrosis. 
[H2] Antigen presentation. In some tissues, PVMs also seem to function as antigen-presenting cells (APCs). For example, in the 
pancreatic islets of Langerhans, PVMs have been shown to constitutively express β-cell antigens in situ and to be able to present them 
to naive T cells in ex vivo assays. In lymph nodes, PVMs adhere to the abluminal side of the endothelial cells of the subcapsular sinus 
and are often termed ‘subcapsular sinus macrophages’. These cells extend processes into the vascular lumen, where they capture 
lymph-borne agents such as viruses through various cell surface receptors. They then translocate these surface-bound substances 
across the sinus floor to present them to follicular B cells33. 
PVMs isolated from other tissues also seem to function as APCs ex vivo, although their ability to do this in situ has yet to be con-
firmed. For example, PVMs isolated from the alveolar interstitium of the lung (a thin area of parenchyma comprising the air–blood 
interface, in which interstitial macrophages are in close proximity to both capillaries and alveoli) present antigens and induce T cell 
activation ex vivo34. Furthermore, peritubular PVMs in the testis35, PVMs in the pineal gland36 and a substantial proportion of PVMs in 
the retina37 express MHC class II molecules — an important feature of APCs38. However, more studies are required to establish 
whether these PVMs can process and present antigens efficiently in vivo. 
[H2] Immune regulation. Importantly, some PVMs can also have immunosuppressive or anti-inflammatory properties. For example, in 
both the lungs and the testes, PVMs release large amounts of IL-10, an immunosuppressive cytokine that is also capable of dampening 
inflammation39–41. In the lungs, this could have beneficial effects such as reducing the migration and maturation of alveolar DCs, thereby 
limiting the onset of respiratory allergies to airborne agents such as pollen, dust mites and mould spores39. In the testes, the expression 
of IL-10 by PVMs, which impairs T cell activation, contributes to making this an immune-privileged organ40,41. This is important, as it 
protects developing spermatocytes — which express new antigens upon meiotic recombination — from destruction by the adaptive 
immune system. IL-10 is also expressed by PVMs in the myocardium; in addition, these cells express V-set and immunoglobulin 
domain-containing protein 4 (VSIG4), which is another negative regulator of T cell activation32. In the BBB, PVMs limit inflammation by 
restraining prostaglandin E2 production by endothelial cells when the latter are exposed to blood-derived bacterial stimuli such as 
lipopolysaccharide (LPS)42. 
In the sinusoids of the spleen and lymph nodes, PVMs produce large amounts of type I interferon after encountering pathogens during 
sepsis, which limit excessive adaptive immune responses43. However, it should be noted that PVMs can also drive adaptive immune 
responses by capturing and transferring antigens to DCs31. Moreover, metallophilic as well as subcapsular macrophages in the spleen 
and lymph nodes are permissive to virus replication, which enables the accumulation of viral antigens for presentation to DCs and 
B cells44,45. The perisinusoidal macrophages in the spleen are also able to take up apoptotic cells and transfer self-antigens to DCs, 
which induces tolerance and prevents autoimmunity46,47. The human spleen lacks a marginal zone sinus, but the capillaries of the 
perifollicular zone are typically covered by a one-layered or two-layered sheath of CD169+ macrophages that are considered to be the 
equivalent of rodent metallophilic macrophages48. 
[H2] Regulation of steroidogenesis and gamete formation. In the adult testis, PVMs are located both in the interstitium (known as 
interstitial PVMs) and along the seminiferous tubules (known as peritubular PVMs)35. Interstitial PVMs are intermingled with Leydig cells 
and capillaries, extend filopodia along the blood vessel walls and promote Leydig cell development and steroidogenesis49,50. This is 
thought to occur through the secretion of 25-hydroxycholesterol, a factor that induces the synthesis of testosterone by Leydig cells; the 
production of 25-hydroxycholesterol is then negatively regulated by testosterone itself49,51. Peritubular PVMs lie on the surface of sem-
iniferous tubules with long processes that make contact with neighbouring blood vessels, and they promote spermatogenesis by re-
leasing factors such as CSF1 and retinoic acid52,53. This was inferred from a study showing that these PVMs express CSF1 and two 
enzymes that are essential for retinoic acid synthesis, retinal dehydrogenase 2 (RALDH2) and retinol dehydrogenase 10 (RDH10). 
Moreover, the density of peritubular PVMs was seen to be greater in segments of the seminiferous tubules that are enriched in undif-
ferentiated spermatogonia35. These observations are supported by the finding that macrophage depletion in the mouse testis caused 
a marked decrease in both the total number and the proliferative activity of undifferentiated spermatogonia in seminiferous tubules35. 
However, some macrophages in the testis are associated with Leydig cells through a unique intercalated adhesion mechanism35. 
These macrophages are not associated with blood vessels per se but could still have some role in regulating the production of testos-
terone. Macrophage depletion removes these cells as well as PVMs, so it is difficult to distinguish the roles of these two macrophage 
populations in the physiology described above. 
In the ovary, PVMs seem to support fertility54, and their number and distribution vary with the oestrus cycle. For example, during 
ovulation, the number of macrophages (most of which are PVMs55–57) increases in the thecal layers of both human and mouse folli-
cles54–56. Once the oocyte is released, macrophages enter the developing corpus luteum and settle along newly formed blood vessels56,57. 
These PVMs promote angiogenesis58 and help to maintain vessel integrity in the corpus luteum59. This is crucial for pregnancy, as the 
establishment of a functional capillary network in the corpus luteum is required for progesterone production and thus successful im-
plantation of the embryo59. 
In summary, it can be seen that PVMs carry out a range of homeostatic and protective functions under steady-state conditions to 
maintain tissue integrity. However, they can also have highly specialized, tissue-specific functions, such as filtering the blood in the 
kidneys, regulating hormone production in the testes and stimulating angiogenesis in the corpus luteum. 
[H1] Functions in diseased tissues 
Here, we outline the important roles of PVMs in several pathological processes, where they seem to be able to either promote or limit 
disease progression. 
[H2] Malignant tumours. A subset of tumour-associated macrophages (TAMs) lies close to blood vessels in mouse and human tumours 
(FIG. 2a); these macrophages were initially characterized by their expression of angiopoietin 1 receptor (TIE2)60. The selective elimination 
of these TIE2+ PVMs in mouse tumours showed that they are important for tumour angiogenesis and growth60–62. Furthermore, their 
numbers positively correlate with microvessel density in both renal and hepatocellular human carcinomas, which suggests that they 
also promote angiogenesis in human tumours63,64. When isolated from mouse mammary tumours, these PVMs were found to express 
higher levels of pro-angiogenic and M2-like genes than their TIE2– (non-perivascular) counterparts65. 
Angiopoietin 2 (ANGPT2), which is often upregulated by tumour endothelial cells, triggers the phosphorylation of TIE2 in macro-
phages and promotes their upregulation of various pro-angiogenic factors, such as the enzymes thymidine phosphorylase and cathep-
sin B. ANGPT2 is also chemotactic for TIE2+ monocytes and macrophages and stimulates their accumulation around blood vessels in 
mouse tumours60,66–68. Therefore, it is tempting to speculate that exposure of TIE2+ PVMs to ANGPT2 in malignant tumours regulates 
the vascular-promoting activities of these cells. Interestingly, TIE2+ PVMs, similarly to TIE2+ TAMs61,62,65,69, facilitate the sprouting70, 
branching3 and anastomosis71 of blood vessels during vascular development in mouse embryos. ANGPT2 also stimulates the immu-
nosuppressive functions of TIE2+ PVMs by upregulating their expression of IL-10, which suppresses T cell proliferation ex vivo67, and 
of CC-chemokine ligand 17 (CCL17), which recruits regulatory T (Treg) cells67. Other mechanisms regulating the phenotype and func-
tions of TIE2+ TAMs include those mediated by CSF1 and invariant natural killer T (iNKT) cells. Perivascular TIE2+ TAMs express 
higher levels of the CSF1 receptor (Csf1r) than do TIE2– TAMs65, and CSF1 has been shown to upregulate the expression of both 
TIE2 and vascular endothelial growth factor A (VEGFA) by TIE2+ TAMs72,73. Furthermore, a recent study has shown that the presence 
of TIE2+ PVMs in mouse prostate tumours is, at least partly, regulated by tumour-infiltrating iNKT cells, as the latter promote the 
selective killing of TIE2+ macrophages to inhibit tumour angiogenesis and growth74. 
High-resolution, intravital imaging of blood vessels in mouse mammary tumours has shown that cancer cells often undergo intrava-
sation at sites of close association between TIE2+ PVMs and endothelial cells. The escape of cancer cells into the circulation at these 
sites in primary tumours leads to the formation of metastases at distant sites, such as the lungs. The PVM–endothelial cell–cancer cell 
clusters have been termed tumour microenvironments of metastasis (TMEMs)75. Increased intravasation occurs at these sites as a 
result of increased vascular permeability induced by both increased expression of VEGFA by TIE2+ PVMs and a decreased number 
of VE-cadherin-based junctional complexes in endothelial cells75. Furthermore, a recent study has shown that CD163+ TAMs express-
ing high levels of insulin-like growth factor 1 (Igf1), a growth and survival factor that is also upregulated by TIE2+ TAMs65, stimulate 
metastasis in primary mouse mammary tumours76. The above findings accord well with the observation that high TMEM density — 
which presumably reflects a high density of PVMs — in human breast carcinomas correlates with increased risk of distant metastasis77. 
PVMs are also present in metastatic mouse and human tumours78–80. MRC1+ PVMs have been reported in both lung metastases of 
a mouse breast cancer (4T1) model and human bone metastases from patients with advanced breast cancer80. Moreover, PVMs occur 
at sites of tumour cell extravasation in lung metastases in a mouse breast cancer (MMTV-PyMT) model. Interestingly, these metastases 
were inhibited when the recruitment of CC-chemokine receptor 2 (CCR2)+ inflammatory monocytes to the lungs was prevented using 
a CCL2-specific antibody or following the conditional knockdown of VEGFA expression by these cells78,79. 
Finally, PVMs have been implicated in tumour resistance to some antivascular agents, such as the vascular-disrupting agent com-
bretastatin-A4-phosphate81. PVMs also contribute to the relapse of mouse tumours after chemotherapy and irradiation80,82,83. This 
effect probably involves CXC-chemokine ligand 12 (CXCL12)-driven recruitment of TIE2+MRC1+CXCR4+ PVMs to the tumour from the 
circulation after the cessation of therapy80,82,83, which then stimulate tumour revascularization and regrowth83. 
[H2] Diseases of the central nervous system. PVMs have been implicated in various pathological conditions of the central nervous 
system (CNS). Their role in these diseases has been identified using clodronate-containing liposomes (CCLs), which, when injected directly 
into the cerebral ventricles, are phagocytosed by PVMs but not microglia, leading to PVM depletion84. The accumulation of amyloid-β 
(Aβ) peptide in and around cerebral blood vessels is a hallmark feature of both Alzheimer disease and cerebral amyloid angiopathy. In a 
transgenic mouse model of such amyloid accumulation, CCL-mediated elimination of PVMs increased Aβ deposition around cerebral 
blood vessels, although it should be noted that meningeal macrophages (which were also depleted in this study) may have contributed 
to this phenomenon85. Interestingly, when chitin was injected into the cerebrospinal fluid of the brain ventricles to selectively stimulate 
brain PVMs to acquire a phenotype resembling M2-like activation86, the clearance of vascular amyloid was increased85. This role for 
PVMs in amyloid clearance is supported by another study, which used a transgenic mouse model of cerebral amyloid accumulation to 
show that PVMs accumulate around areas of amyloid deposition and upregulate their expression of scavenger receptor class B mem-
ber 1 (SRB1)87. When mice in this model were crossed with a transgenic mouse line lacking SRB1, amyloid deposition in the brain was 
increased, which suggests that SRB1 expression by PVMs mediates their ability to clear amyloid87. 
However, as well as this protective role in scavenging amyloid, brain PVMs can also accelerate the neurovascular dysfunction that 
occurs in areas of the brain in which amyloid deposits occur. This is because amyloid-mediated activation of CD36 stimulates PVMs 
to release reactive oxygen species (ROS), leading to increased cerebrovascular oxidative stress88. Similarly, brain PVMs have a role 
in the neurocognitive alterations that are related to hypertension, as depletion of PVMs in mouse models of chronic hypertension 
reduces vascular oxidative stress and rescues cognitive function89. Studies of bone marrow chimeric mice have shown that the cogni-
tive dysfunction is mediated by the activation of type 1 angiotensin II receptors on PVMs by angiotensin II, which is known to increase 
blood pressure by stimulating the contraction of vascular smooth muscle cells. The PVM activation results in the generation of NADPH 
oxidase 2 (NOX2; also known as CYBB)-dependent ROS89, which promote vascular dysfunction. 
Brain PVMs also have a role in protecting the brain during bacterial meningitis. They do so by facilitating the influx of neutrophils 
into the brain to counteract invading bacteria. This was shown in a rat model of streptococcal meningitis, in which CCL-mediated 
depletion of brain PVMs reduced the influx of neutrophils across the BBB into the brain, increased bacterial load in the cerebrospinal 
fluid and increased symptoms associated with infection90. Paradoxically, the elimination of PVMs was accompanied by increased levels 
of CXCL2, which is a chemotactic factor for neutrophils, as well as leukocyte adhesion molecules in endothelial cells. These apparently 
contradictory results show that, in the absence of PVMs, compensatory mechanisms occur that may support neutrophil influx. However, 
the role of PVMs in protection from, versus facilitation of, infection may vary with the type of pathogen, as CCL-mediated depletion of 
brain PVMs increased the survival of mice with vesicular stomatitis virus-induced encephalitis91. Similarly, brain PVMs have been 
implicated in the pathogenesis of encephalitis associated with HIV-1 infection, as these PVMs seem to host a viral reservoir in the 
brain92,93. In rhesus macaques infected with a simian immunodeficiency virus (SIV), both SIV RNA and the viral glycoprotein 120 
(gp120) were abundant in PVMs but were barely detectable in CD163– microglia in the brain parenchyma92,93. Moreover, CD163+ 
PVMs in encephalitic lesions express the proliferation marker Ki-67 when infected with HIV or SIV94, which indicates that these cells 
may proliferate under such conditions, thereby increasing the cellular reservoir of the virus. Interestingly, these studies suggest that 
brain PVMs, similarly to peri-sinusoidal PVMs in the spleen and lymph nodes, can function as a reservoir for viruses. 
Brain PVMs may also have a role in the progression of multiple sclerosis. These cells are typically CD163+HLA-DR+ (REF.95) and have 
been found to accumulate around blood vessels in areas of demyelination in the CNS of patients with multiple sclerosis. They present 
peptides derived from myelin basic protein on the MHC class II molecule HLA-DR96, which could lead to an autoimmune reaction to 
myelin and thereby accelerate disease progression. This potential role for PVMs is also supported by studies of rats with experimental 
autoimmune encephalomyelitis, a commonly used model of multiple sclerosis, in which the number of PVMs in the brain is increased; 
the selective elimination of PVMs in this model reduces the progression of the disease97. In another study, it was reported that in rat 
models, PVMs strongly upregulate expression of CCL2 and CCL3, which suggests that these chemokines maypromote monocyte 
recruitment to the brain during multiple sclerosis98. 
Finally, PVMs have been implicated in protecting the brain from the deleterious effects on glucose uptake and from cognitive im-
pairment in mice fed a high-fat diet99. Normally, glucose transporter type 1, erythrocyte/brain (GLUT1; also known as SLC2A1) shuttles 
glucose across endothelial cells of the BBB into the brain. This process was reduced in mice fed a high-fat diet, triggering a compen-
satory increase of VEGFA expression by PVMs in the BBB, which in turn restored GLUT1 expression and cerebral glucose metabolism. 
When VEGFA expression by PVMs was ablated, GLUT1 expression remained low in the BBB and the integrity of the BBB was com-
promised, leading to cognitive impairment of the mice. Thus, PVMs in the BBB might have a role in limiting neurodegeneration in 
obesity. 
[H2] Inflammatory conditions. PVMs may also promote rather than dampen inflammation. This can be beneficial under some conditions 
but when uncontrolled can lead to chronic inflammation and contribute to disease progression. 
During experimentally induced inflammation of the retina in rabbits, PVMs increase their expression of MHC class II molecules and 
accumulate in the injured area100. PVMs also show increased motility and accumulation when the blood–retinal barrier is experimentally 
disrupted in mice; retinal PVMs move into the injured area along blood vessels from non-disrupted areas19. In both cases, PVMs 
attempt to limit the effects of the injury or inflammation by phagocytosing dead and dying cells or by limiting the extravasation of blood-
derived materials19,100. Alternatively, in chronic inflammation of the uvea (experimental autoimmune uveitis) in rats, retinal PVMs support 
retinitis by releasing pro-inflammatory cytokines such as IL-1β and tumour necrosis factor101. 
In a mouse model of LPS-induced otitis, PVMs are activated, and this correlates with the vascular leakage of the intrastrial fluid–
blood barrier and hearing loss102. Furthermore, in a model of acoustic trauma, PVMs detach from capillary walls and decrease their 
release of PEDF, which in turn increases vascular permeability in the cochlea103 (FIG. 2b). Finally, the contribution of cochlear PVMs to 
age-related hearing loss (presbycusis) was inferred from the observation that these cells are reduced in number — and have less 
physical contact with endothelial cells — in aged mice104. 
The deposition of immune complexes in the renal interstitium contributes to autoimmune diseases of the kidneys. Recently, a com-
bination of tissue immunostaining and intravital imaging showed that renal PVMs lying between the endothelium and the basement 
membrane of glomerular and peritubular capillaries take up, via Fcγ receptor IV (FcγRIV), immune complexes delivered into the inter-
stitium from the blood by trans-endothelial transport. This then triggers the onset of inflammation20 (FIG. 2c). 
There are also studies in mice showing that CD4hi PVMs in the dermis of the skin can promote inflammation by supporting the trans-
endothelial migration of neutrophils in dermal postcapillary venules105, which is a key event in the inflammatory response against 
pathogens. In DPE–GFP mice, which express green fluorescent protein (GFP) under the control of the Cd4 enhancer and promoter, 
infection with Staphylococcus aureus promotes neutrophil extravasation specifically through postcapillary dermal venules surrounded by 
clusters of GFP+ PVMs that express neutrophil chemoattractants105. Interestingly, GFP+ PVMs could be lysed by a toxin, Hle, produced 
by S. aureus. When mice were infected with Hle-deficient bacteria, PVMs were not lysed, resulting in increased neutrophil extravasa-
tion105. Therefore, bacterial products such as Hle can protect bacteria from host defences106 by ablating skin PVMs, which results in 
the reduced recruitment of neutrophils. 
Skin PVMs are also important for the induction of DC clustering around postcapillary venules — an area where effector T cells 
extravasate into inflamed skin during inflammation107. Indeed, PVMs could have a role in the induction of skin allergies, as a mouse 
model of contact hypersensitivity showed that PVMs attract DCs around postcapillary venules through the release of CXCL2 in re-
sponse to IL-1α produced by activated keratinocytes. This DC clustering was abrogated by inhibition of either IL-1 receptor (IL-1R) or 
CXC-chemokine receptor 2 (CXCR2)108. Therefore, skin PVMs facilitate DC–T cell interactions and, in turn, promote adaptive immune 
responses. 
A recent study has suggested that PVMs in the lung interstitium have an important role in the pathogenesis of lung fibrosis109. In a 
mouse model of lung fibrosis, intratracheal injection of bleomycin to induce lung injury increased the number of vascular endothelial 
growth factor receptor 1 (VEGFR1)-expressing PVMs present around pulmonary capillaries. These cells then stimulated WNT–
β-catenin-dependent upregulation of the Notch ligand Jagged 1 in neighbouring endothelial cells, which, in turn, stimulated Notch 
signalling in perivascular fibroblasts to promote lung fibrosis (FIG. 2d). However, it is not clear whether these pro-fibrotic PVMs in the 
lungs derive from monocytes recruited from the circulation or lung-resident PVMs. Also, it remains to be seen whether PVMs have a 
similar role in regulating fibrotic reactions in other tissues110. 
[H2] Type 1 diabetes. Type 1 diabetes is an autoimmune disease characterized by the infiltration of pancreatic islets by immune cells, 
resulting in T cell-mediated destruction of insulin-producing β-cells. Intravital imaging of islets in the non-obese diabetic (NOD) mouse 
model of type 1 diabetes has led to speculation regarding a possible role for PVMs in the pathogenesis of this disease. For example, 
there is close interaction between PVMs and T cells in the pancreatic islets111, and at the onset of pancreatic autoimmunity, both CD4+ 
and CD8+ T cells make close contacts with islet PVMs. Thus, the PVMs may support diabetogenesis by presenting islet-derived anti-
gens to T cells (as they are able to do so ex vivo). Indeed, the pancreatic islets of Nox1–/− mice — which lack NADPH oxidase 1 (NOX1)-
derived superoxide (which is important for the pro-inflammatory, M1-like activation status of islet PVMs112,113) — contain PVMs that are 
less pro-inflammatory, as assessed by their gene expression profile113. This contrasts with NOD mice expressing normal levels of 
NOX1, which have M1-like islet PVMs expressing high levels of pro-inflammatory genes. NOX1-proficient NOD mice develop diabetes 
more rapidly than NOD mice lacking NOX1 (REF.114). Moreover, when NOX1-deficient NOD mice are infected with the diabetogenic 
agent coxsackie virus B3, they remain resistant to virus-induced autoimmune diabetes, and their islet PVMs fail to induce a strong pro-
inflammatory response while retaining the ability to clear virus113. It is possible, therefore, that certain viral infections may be linked to 
the onset of type 1 diabetes115 and that this process involves the activation of pro-inflammatory islet PVMs, which, in turn, promote 
autoimmunity. 
In summary, PVMs have been implicated in a wide variety of disease conditions. Whereas in malignant tumours, multiple sclerosis, 
HIV infection and type 1 diabetes, PVMs seem to promote disease progression, in Alzheimer disease and bacterial meningitis, they 
can be protective and limit, but not prevent, the onset of tissue pathology. 
[H1] Concluding remarks 
As outlined above, PVMs carry out several important functions at the interface between tissues and the blood, including limiting vascular 
permeability to maintain tissue integrity, sensing and clearing potential blood-borne pathogens rapidly as they enter tissues and limiting 
inflammation and autoimmunity. The study of these cells is a rapidly expanding field, and a picture is emerging of the factors in the 
perivascular niche that regulate their functions in both steady-state and diseased tissues. Endothelial cell-derived cytokines such as 
ANGPT2, CXCL12 and CSF1 have been shown to support the proliferation, differentiation and retention of PVMs in some tissues, and 
extracellular vesicles can also transfer signalling molecules and genetic information between these two cell types2,8,116. 
By contrast, little is known about how pericytes interact with PVMs in the vascular niche or the extent to which this interaction 
regulates the maintenance and functions of either cell type. Both PVMs and pericytes seem to contribute to the control of vascular 
permeability, raising the intriguing question of whether their contribution to this process differs between tissues or even in different 
areas of the same tissue. Another unanswered question concerns whether the functions of PVMs vary with their position within the 
vascular tree (for example, capillaries versus venules) of a given tissue or organ. We also know little about whether PVMs interact with 
intravascular macrophages, such as Kupffer cells in the liver, when both are in contact with the same blood vessel. Although intravas-
cular macrophages have some functional similarities with PVMs, they also carry out distinct and specialized tasks (BOX 2), some of 
which may depend on their exposure to the constituents of the blood, the sheer stress of being under flow and/or differences in their 
ontogeny. 
In certain diseased tissues, the selective depletion or re-education of PVMs, such as those driving angiogenesis and metastasis in 
tumours, triggering inflammation in the kidneys or functioning as a viral reservoir in the brain, could provide therapeutic benefit. How-
ever, targeting PVMs selectively is currently challenging, as PVMs share many cell surface receptors (TABLES 1,2), transcriptional pro-
grammes and signalling pathways with other macrophage populations117. For example, some studies have attempted to selectively 
target PVMs in the mouse brain using CCLs. However, this approach probably depletes both meningeal macrophages and PVMs5,90,91. 
Interestingly, a recent study has shown that PVMs can derive from other macrophages in the same tissue, highlighting the interrela-
tionship between motile TAMs and sessile PVMs in mouse mammary tumours118. Monocyte-derived TAMs were seen to be attracted 
to blood vessels in response to CXCL12 expressed by perivascular fibroblasts. Upon reaching the perivascular niche, these motile 
TAMs then became sessile PVMs. This exciting new finding argues in favour of the notion that PVMs may sometimes represent a 
‘snapshot’ of a highly dynamic process. It remains to be seen whether PVMs in healthy tissues can also derive from monocyte-derived 
macrophages elsewhere in the same tissue or organ. Although there is evidence for PVMs in the myocardium being derived from 
circulating monocytes119 (BOX 1), this may not be ubiquitous, as other studies have shown that PVMs in the healthy brain, pancreas and 
testis are derived from the local proliferation of yolk sac-derived progenitors69,120,121 (BOX 1). However, this does not exclude the possi-
bility that self-renewing, yolk sac-derived macrophages can migrate into the perivascular niche under some conditions. Other studies 
have tried to separate PVMs from non-PVM macrophages in the mouse cortex on the basis of CD45 expression. However, use of 
fluorescence-activated cell sorting (FACS) to separate CD45hi macrophages (mainly PVMs) from CD45low microglia resulted in enrich-
ment for rather than isolation of pure PVMs120. A recent study took a different approach to isolate various types of perivascular cell 
situated along blood vessels in the healthy mouse cortex. This involved first isolating the brain vasculature, enzymatically dispersing 
the cells attached to these vessels and then analysing their gene expression through single cell RNA sequencing122. 
In other tissues such as mouse tumours, earlier studies have used Tie2–GFP reporter mice to isolate TIE2+ PVMs68. As PVMs in 
some tissues express high levels of MRC1 (TABLES 1,2), it may be possible to use fluorescently labelled high-molecular-mass dextran to 
isolate these cells (or to target them with dextran-coated nanoparticles), as this form of dextran is selectively ingested by MRC1+ PVMs 
in mouse mammary tumours123. However, the use of dextran to label PVMs may be restricted to diseased tissues with increased vessel 
permeability such as malignant tumours, where passage of dextran across the vasculature into the perivascular space is assured. 
As mentioned previously, some studies have shown that PVMs in certain tissues express markers that are consistent with an M2-like 
phenotype, although mixed M1–M2 phenotypes predominate in most of the tissues and organs that have been examined (TABLES 1,2). 
This is of interest because recent experimental data suggest that, in order to limit vascular permeability, PVMs need to be M2-skewed13. 
However, there is now considerable evidence that PVMs in tumours are largely M2-skewed68 and that they promote, rather than limit, 
vascular permeability75. This means that the effects of PVMs on vascular permeability may depend upon their local environment. 
Inhibitors of CSF1R have been found to induce facial or peri-orbital oedema in a substantial proportion of patients124. Notably, CSF1R 
inhibitors deplete macrophages from several organs125, so oedema formation may be explained by the loss of vascular integrity and 
the increased permeability at certain as-yet-undetermined sites126. Deciphering the key factors that regulate the development and 
function of PVMs in either normal tissues or tumours might help to develop drugs that selectively target pro-tumoural PVMs while 
sparing PVM populations that are likely to maintain vascular integrity in normal organs. 
We still have much to learn about the biology of PVMs. Increasing use of high-resolution imaging techniques and precision tools for 
gene and protein analysis at the single cell level will, hopefully, generate new insights into the functions of these cells and highlight 
targets for therapeutic intervention. 
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Box 1 | Ontogeny of perivascular macrophages 
As is the case for other tissue-resident macrophage populations, the exact origin(s) of perivascular macrophages (PVMs) in most tissues are still poorly understood. 
However, this has been described in more detail for several tissues. 
[b1] Brain 
Initial studies using bone marrow transplantation (BMT) seemed to show that PVMs in the healthy adult mouse brain originate from precursors in the bone mar-
row127. However, more recent fate-mapping studies have shown that brain PVMs actually originate from yolk sac-derived, erythromyeloid progenitors that are 
seeded in brain tissue during early embryogenesis120. This apparent discrepancy between the studies may be due to the fact that BMT following whole-body irradia-
tion can lead to the atypical recruitment of monocytes into the central nervous system128. 
[b1] Heart 
There are two subsets of PVMs in the myocardium — a more abundant subset derived from embryonic yolk sac progenitors that self-renew during adulthood and a 
smaller subset derived from haematopoietic stem cell-derived precursors in the fetal liver. The latter subset depends on circulating monocytes for maintenance119. 
These results were obtained from parallel in vivo cell tracking, parabiosis, bone marrow transplants and fate-mapping studies119. Moreover, following the disruption 
of homeostasis, monocyte-derived macrophages were not only recruited to the myocardium but also permanently replaced the embryonically derived, resident mac-
rophage populations119. 
[b1] Endocrine pancreas 
PVMs in pancreatic islets seem to be derived mainly from yolk sac precursors that self-renew throughout adult life. After myeloablation and BMT, bone marrow-
derived precursors were seen to be able to replace pancreatic islet PVMs, but parabiosis studies showed that most islet PVMs are long lived, self-replicating cells and 
cannot be replaced by blood monocytes under steady state (only after irradiation and/or myeloablation)121. 
[b1] Testis 
In the testis, interstitial PVMs derive from yolk sac progenitors, whereas peritubular PVMs are exclusively constituted postnatally from bone marrow-derived pro-
genitors69. In adults, the total number of PVMs in the testis is maintained by self-renewal, and these PVMs can only partially be replenished by circulating mono-
cytes69. 
[b1] Tumours 
Although the origin of angiopoietin 1 receptor (TIE2)+ PVMs in tumours has not been fully defined, some have suggested that they derive from 
Ly6ClowCX3CR1hiCCR2low monocytes, which have a similar phenotype62,67. A minor subset of human monocytes (<25%) expresses TIE2 and could, therefore, be a 
circulating pool of potential precursors for TIE2+ PVMs61,62,66. However, in a mouse model of pancreatic ductal adenocarcinoma, tumour-associated macrophages 
(TAMs) have recently been shown to be derived from both circulating monocytes and yolk sac-derived macrophages129. PVMs were not looked at per se in this 
study, so it is not known whether they fall into one or both TAM subsets in this type of tumour. 
Box 2 | Comparison of the main functions of perivascular and intravascular macrophages in the liver, spleen and lymph nodes under steady-
state conditions 
[b1] Functions of perivascular macrophages 
• Regulation of vascular permeability13 
• Phagocytosis of pathogens and other potentially harmful blood-borne agents18–23,25,27–30 
• Antigen presentation11,24,26,29,33,34,36,37 
• Maintenance of immune tolerance in some tissues through local immunosuppression and participation in tissue–blood barrier functions18,19,21,40,42 
• Limiting inappropriate inflammation32,39,40,42,46,47, with the exception of perivascular macrophages in pancreatic islets, which express pro-inflammatory genes (TA-
BLE 1) 
[b1] Functions of intravascular macrophages 
• Phagocytosis of pathogens and other potentially harmful blood-borne agents, in the case of Kupffer cells* (liver), red pulp macrophages (spleen) and medullary 
macrophages in the lymph nodes29,30,130 
• Destruction of aged platelets and erythrocytes (a process known as haemocatheresis) and the recycling of iron, in the case of Kupffer cells and red pulp macro-
phages27,30,131 
• Antigen presentation, in the case of Kupffer cells132 
• Uptake and metabolism of lipids, in the case of Kupffer cells133 
*Kupffer cells sometimes extend their filopodia through the perivascular space of Disse. However, because their cell bodies are always on the luminal side of the liver sinusoids, 
they are intravascular macrophages134. 
Fig. 1 | Interactions between perivascular macrophages and blood vessels in steady-state tissues. Transmission electron microscopy has been used 
to provide unequivocal evidence of the various sites that are occupied by macrophages in the perivascular niche in the following tissues. a | In the brain, peri-
vascular macrophages (PVMs) lie under the basement membrane alongside pericytes. b | In the kidneys, PVMs also lie under the basement membrane on the 
abluminal side of endothelial cells and extend long filopodia along the vessel length. c | In the retina, PVMs lie on the outer surface of the basement membrane, 
where they scavenge along the outside of the retinal vessels. They often contain autofluorescent inclusions. d | In the pancreatic islets of Langerhans, PVMs 
make contact with endothelial cells and often extend protrusions into the vessel lumen. In other tissues (not shown), PVMs make contact with, or are found in 
close proximity to, the abluminal surface of blood vessels (for example, in the dermis of the skin, PVMs are usually found within 15 µm of vessels), but the 
specific nature of their interaction with the endothelium (in other words, whether they reside below the basement membrane or on its abluminal surface) has yet 
to be determined by ultrastructural studies. 
Fig. 2 | Role of perivascular macrophages in diseased tissues. a | In malignant tumours, angiopoietin 1 receptor (TIE2)+ perivascular macrophages 
(PVMs) stimulate several tumour-promoting processes in response to cytokines that are present in the perivascular niche such as angiopoietin 2 (ANGPT2) 
(which binds TIE2), macrophage colony-stimulating factor 1 (CSF1) (which binds CSF1 receptor (CSF1R)) and CXC-chemokine ligand 12 (CXCL12) (which 
binds CXC-chemokine receptor 4 (CXCR4)). b | In acoustic trauma, PVMs detach from capillaries and decrease their release of pigment epithelium-derived 
factor (PEDF). This results in decreased stability of tight junctions between blood vessel endothelial cells and increased vascular permeability, which compro-
mises the integrity of the labyrinth–blood barrier in the cochlea and can lead to hearing loss. c | In renal inflammation, PVMs in the kidneys ingest circulating 
immune complexes — which are taken up from the blood by endothelial cells — through Fcγ receptor IV (FcγRIV). This induces inflammation, including the 
recruitment of monocytes and neutrophils into the renal interstitium. d | After lung injury (here, induced experimentally by bleomycin injection), vascular endo-
thelial growth factor receptor 1 (VEGFR1)+ PVMs in the perivascular niche release WNT3A, which induces a β-catenin-mediated signalling pathway in blood 
vessel endothelial cells that upregulates their expression of Jagged 1. This triggers (through Notch signalling) the production and release of collagen from peri-
vascular fibroblasts and promotes fibrosis. PEDFR, PEDF receptor. 
Table 1 | Features of perivascular macrophages in steady-state adult tissues (mouse and human) 
Healthy adult tissue Specie
s 
Phenotype Activation markers expressed Gene expre







Retina Mouse CD45hiAIF1–F4/80+ SRA1+MHCIIhi ND 
Human CD45+S22+ HLAIIhi ND 
Cochlea Mouse F4/80+CD68+ SRA1+SRB1+ ND 
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ABCA1, ATP-binding cassette subfamily A member 1; AIF1, allograft inflammatory factor 1; Arg1, arginase 1; C1q, complement component 1q; C3, complement compo-
nent 3; C3ar1, complement component 3a receptor 1; CR-L, ligand for cysteine-rich domain of mannose receptor; CSF1R, macrophage colony-stimulating factor 1 recep-
tor; CX3CR1, CX3-chemokine receptor 1; Cxcl, CXC-chemokine ligand; Dectin2, dendritic cell-associated C-type lectin 2 (also known as CLEC6A); F13A, coagulation 
factor XIII A; Fizz1, resistin-like-α (also known as Retnla); HLAII, HLA class II; Hpgd, hydroxyprostaglandin dehydrogenase 15; Igf1, insulin-like growth factor 1; 
Ly6C, lymphocyte antigen 6C; LYVE1, lymphatic vessel endothelial hyaluronic acid receptor 1; MARCO, macrophage receptor with collagenous structure; Mgl1, macro-
phage galactose-type C-type lectin 1 (also known as Clec10a); MHCII, MHC class II; Mmp13, matrix metalloproteinase 13; MRC1, macrophage mannose receptor 1; ND, 
not determined; Nrp1, neuropilin 1; PVM, perivascular macrophage; Slc40a1, solute carrier family 40 (iron-regulated transporter), member 1; Spic, Spi-C transcription 
factor (Spi-1/PU.1 related); SRA1, scavenger receptor class A member 1; TIM4, T cell immunoglobulin mucin receptor 4 (also known as TIMD4); Tlr4, Toll-like receptor 
4; Tnf, tumour necrosis factor; Trem2, triggering receptor expressed on myeloid cells 2; Vsig4, V-set and immunoglobulin domain-containing protein 4; Ym1, chitinase-
like 3 (also known as Chil3). 
Table 2 | Features of perivascular macrophages in diseased adult tissues (mouse and human) 
Diseased tissue Species Phenotype Activation markers expressed Gene exp










CXCR4+MRC1+ TIE2 and V
Neurocognitive alter-
ations related to hy-
pertension (brain) 
Mouse CD45hiCD11b+AIF1– MRC1+LYVE1+ ND 
Multiple sclerosis 
(brain) 
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 ND ND 
ABCA1, ATP-binding cassette subfamily A member 1; AIF1, allograft inflammatory factor 1; Arg1, arginase 1; Ccl, CC-chemokine ligand; CCR, CC-chemokine recep-
tor; Cox2, cyclooxygenase 2; Csf1r, macrophage colony-stimulating factor 1 receptor; Ctsb, cathepsin B; CX3CR1, CX3-chemokine receptor 1; Cxcl, CXC-chemokine 
ligand; CXCR4, CXC-chemokine receptor 4; HLAII, HLA class II; Icam1, intercellular adhesion molecule 1; Igf1, insulin-like growth factor 1; LYVE1, lymphatic vessel 
endothelial hyaluronic acid receptor 1; MHCII, MHC class II; Mmp9, matrix metalloproteinase 9; MRC1, macrophage mannose receptor 1; Msr1, macrophage scavenger 
receptor 1; ND, not determined; Nrp1, neuropilin 1; Pdgfb, platelet-derived growth factor B; Pgf, placental growth factor; SIV, simian immunodeficiency virus; Stab1, 
stabilin 1; TIE2, angiopoietin 1 receptor; Tlr, Toll-like receptor; TNF, tumour necrosis factor; VEGFA, vascular endothelial growth factor A; Vegfb, vascular endothelial 
growth factor B; VEGFR2, vascular endothelial growth factor receptor 2 (also known as KDR). 
Glossary 
Stria vascularis 
A highly vascularized area in the lateral wall of the cochlea (a sensory organ of the inner ear) that produces endolymph and is responsible for generating the endocochlear po-
tential that is required for the transduction of sound. 
Blood–brain barrier 
(BBB). A tightly regulated, protective, vascular interface that separates the peripheral blood and central nervous system. 
Alternative (M2) macrophage activation 
Activation to a group of polarized, anti-inflammatory phenotypes (M2a, M2b and M2c) that is induced by type 2 cytokines such as IL-4 and IL-13 (M2a), immune complexes and 
Toll-like receptor or IL-1 receptor ligands (M2b), and IL-10 and glucocorticoids (M2c). 
Classical (M1) macrophage activation 
Activation to a polarized, pro-inflammatory and antimicrobial phenotype that is induced by the type 1 cytokine interferon-γ, various microbial molecules (such as lipopolysaccha-
ride) or other inflammatory cytokines (such as tumour necrosis factor and granulocyte–macrophage colony-stimulating factor). 
Islets of Langerhans 
Regions of the pancreas that contain the hormone-producing cells. 
Reticuloendothelial system 
A network of cells sharing a common function, namely, phagocytosis. 
Bowman capsule 
A cup-like sac at the beginning of the tubular component of a nephron in the mammalian kidney that encloses a cluster of microscopic blood vessels known as the glomerulus 
and filters the blood to form urine. 
Dense core granules 
Subcellular organelles in the ฀β-cells of the pancreatic islets that store and release various peptide hormones, including insulin. 
Subcapsular sinus 
The space between the capsule and the cortex of a lymph node that enables the free movement of lymphatic fluid. 
Sinusoids 
Capillaries with a fenestrated, discontinuous endothelium. 
Seminiferous tubules 
Structures in the testis that contain epithelium enveloping and supporting germ cells that are undergoing progressive differentiation and development into mature spermatozoa. 
Leydig cells 
Cells in the connective tissue between the seminiferous tubules that produce testosterone. 
Corpus luteum 
A temporary, hormone-secreting structure that develops in an ovary after an ovum has been discharged at ovulation. 
Intravasation 
Movement of cells through a basement membrane into a blood or lymphatic vessel. 
Clodronate-containing liposomes 
(CCLs). Synthesized liposomes containing the bisphosphonate clodronate, which kills macrophages when taken up by them. 
Cerebral amyloid angiopathy 
A condition in which β-amyloid is deposited around the small-sized and mid-sized arteries (and, sometimes, the veins) of the cerebral cortex. 
Experimental autoimmune uveitis 
A mouse or rat model of inflammation in the uveal component of the eye caused by an autoimmune reaction to self antigens. 
 
